Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age
Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-positive and age at onset ≥60 years are poor prognosis factors in polymyositis (PM) and dermatomyositis (DM) associated with interstitial lung disease (ILD) among Japanese patients. However, the influence of age on the clinical feat...
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2021, Vol.31 (1), p.177-185 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 185 |
|---|---|
| container_issue | 1 |
| container_start_page | 177 |
| container_title | Modern rheumatology |
| container_volume | 31 |
| creator | Yamaguchi, Koichi Yamaguchi, Aya Onuki, Yuji Itai, Miki Kashiwagi, Chiharu Takehara, Kazutaka Aoki, Shuhei Kanaya, Azusa Taguchi, Kohei Umetsu, Kazue Oshima, Kazuma Uchida, Megumi Kimura, Hayato Kasahara, Morimitsu Takemura, Masao Hara, Kenichiro Sekiguchi, Akiko Motegi, Sei-ichiro Muro, Yoshinao Nakasatomi, Masao Motohashi, Rena Sakairi, Toru Nakagawa, Junichi Hiromura, Keiju Obokata, Masaru Kurabayashi, Masahiko Maeno, Toshitaka |
| description | Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-positive and age at onset ≥60 years are poor prognosis factors in polymyositis (PM) and dermatomyositis (DM) associated with interstitial lung disease (ILD) among Japanese patients. However, the influence of age on the clinical features of anti-MDA5 autoantibody-positive patients with DM remains unclear.
We retrospectively examined 40 patients with DM and anti-MDA5 autoantibodies according to age. We compared patients aged |
| doi_str_mv | 10.1080/14397595.2020.1740400 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_32149542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2375505912</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-a231337466763227f43e365b6a8a4650f7e03881ae61bd2c336532f8ab9398863</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEYnz9BFCPXDqSuEmbG2h8SkNwgHPktgkEtQ0kmdD-PR3bOHKyZT-vLT2EnDI6ZbSiF6wAVQolppzycVQWtKB0hxys5nkpqdrd9iM0IYcxflAKQlVqn0yAs0KJgh-Q51nnBtdgl1mDaRFMzLzNWhN6TL5f-uiSixnG6BuHybTZt0vvGQ7J5Y_XV-K3q33rxly9zPDNHJM9i100J5t6RF5vb15m9_n86e5hdjXPG1A05ciBAZSFlKUEzktbgAEpaokVFlJQWxoKVcXQSFa3vIFxCdxWWCtQVSXhiJyv734G_7UwMenexcZ0HQ7GL6LmUApBhWJ8RMUabYKPMRirP4PrMSw1o3olU29l6pVMvZE55s42LxZ1b9q_1NbeCFyuATdYPxr79qFrdcJl54MNODQuavj_xw9eJoGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2375505912</pqid></control><display><type>article</type><title>Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Yamaguchi, Koichi ; Yamaguchi, Aya ; Onuki, Yuji ; Itai, Miki ; Kashiwagi, Chiharu ; Takehara, Kazutaka ; Aoki, Shuhei ; Kanaya, Azusa ; Taguchi, Kohei ; Umetsu, Kazue ; Oshima, Kazuma ; Uchida, Megumi ; Kimura, Hayato ; Kasahara, Morimitsu ; Takemura, Masao ; Hara, Kenichiro ; Sekiguchi, Akiko ; Motegi, Sei-ichiro ; Muro, Yoshinao ; Nakasatomi, Masao ; Motohashi, Rena ; Sakairi, Toru ; Nakagawa, Junichi ; Hiromura, Keiju ; Obokata, Masaru ; Kurabayashi, Masahiko ; Maeno, Toshitaka</creator><creatorcontrib>Yamaguchi, Koichi ; Yamaguchi, Aya ; Onuki, Yuji ; Itai, Miki ; Kashiwagi, Chiharu ; Takehara, Kazutaka ; Aoki, Shuhei ; Kanaya, Azusa ; Taguchi, Kohei ; Umetsu, Kazue ; Oshima, Kazuma ; Uchida, Megumi ; Kimura, Hayato ; Kasahara, Morimitsu ; Takemura, Masao ; Hara, Kenichiro ; Sekiguchi, Akiko ; Motegi, Sei-ichiro ; Muro, Yoshinao ; Nakasatomi, Masao ; Motohashi, Rena ; Sakairi, Toru ; Nakagawa, Junichi ; Hiromura, Keiju ; Obokata, Masaru ; Kurabayashi, Masahiko ; Maeno, Toshitaka</creatorcontrib><description>Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-positive and age at onset ≥60 years are poor prognosis factors in polymyositis (PM) and dermatomyositis (DM) associated with interstitial lung disease (ILD) among Japanese patients. However, the influence of age on the clinical features of anti-MDA5 autoantibody-positive patients with DM remains unclear.
We retrospectively examined 40 patients with DM and anti-MDA5 autoantibodies according to age. We compared patients aged <60 and ≥60 years with respect to clinical features including laboratory test findings, high-resolution lung computed tomography data, treatment content, and complications such as infections and prognosis. We also examined clinical features between surviving and deceased patients in the older patient group.
Of 40 enrolled patients, 13 were classified as old and 27 as young. Older patients had significantly fewer clinical symptoms including arthralgia/arthritis (p < .01), skin ulceration (p = .02), and higher mortality than younger patients (p = .02) complicated with rapidly progressive ILD (RP-ILD), combination immunosuppressive therapy, and strictly controlled infections.
Clinical features and mortality of anti-MDA5 autoantibody-positive DM patients were influenced by age. Patients aged ≥60 years had a worse prognosis, and combination immunosuppressive therapy was often ineffective for RP-ILD in older patients.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1080/14397595.2020.1740400</identifier><identifier>PMID: 32149542</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adult ; Age Factors ; Aged ; Anti-MDA5 autoantibody ; Autoantibodies - immunology ; Dermatomyositis - drug therapy ; Dermatomyositis - epidemiology ; Dermatomyositis - immunology ; Dermatomyositis - pathology ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Interferon-Induced Helicase, IFIH1 - immunology ; Male ; Middle Aged ; Mortality ; myositis-associated antibody ; older people ; rapidly progressive interstitial lung disease</subject><ispartof>Modern rheumatology, 2021, Vol.31 (1), p.177-185</ispartof><rights>2020 Japan College of Rheumatology 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-a231337466763227f43e365b6a8a4650f7e03881ae61bd2c336532f8ab9398863</citedby><cites>FETCH-LOGICAL-c390t-a231337466763227f43e365b6a8a4650f7e03881ae61bd2c336532f8ab9398863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32149542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaguchi, Koichi</creatorcontrib><creatorcontrib>Yamaguchi, Aya</creatorcontrib><creatorcontrib>Onuki, Yuji</creatorcontrib><creatorcontrib>Itai, Miki</creatorcontrib><creatorcontrib>Kashiwagi, Chiharu</creatorcontrib><creatorcontrib>Takehara, Kazutaka</creatorcontrib><creatorcontrib>Aoki, Shuhei</creatorcontrib><creatorcontrib>Kanaya, Azusa</creatorcontrib><creatorcontrib>Taguchi, Kohei</creatorcontrib><creatorcontrib>Umetsu, Kazue</creatorcontrib><creatorcontrib>Oshima, Kazuma</creatorcontrib><creatorcontrib>Uchida, Megumi</creatorcontrib><creatorcontrib>Kimura, Hayato</creatorcontrib><creatorcontrib>Kasahara, Morimitsu</creatorcontrib><creatorcontrib>Takemura, Masao</creatorcontrib><creatorcontrib>Hara, Kenichiro</creatorcontrib><creatorcontrib>Sekiguchi, Akiko</creatorcontrib><creatorcontrib>Motegi, Sei-ichiro</creatorcontrib><creatorcontrib>Muro, Yoshinao</creatorcontrib><creatorcontrib>Nakasatomi, Masao</creatorcontrib><creatorcontrib>Motohashi, Rena</creatorcontrib><creatorcontrib>Sakairi, Toru</creatorcontrib><creatorcontrib>Nakagawa, Junichi</creatorcontrib><creatorcontrib>Hiromura, Keiju</creatorcontrib><creatorcontrib>Obokata, Masaru</creatorcontrib><creatorcontrib>Kurabayashi, Masahiko</creatorcontrib><creatorcontrib>Maeno, Toshitaka</creatorcontrib><title>Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-positive and age at onset ≥60 years are poor prognosis factors in polymyositis (PM) and dermatomyositis (DM) associated with interstitial lung disease (ILD) among Japanese patients. However, the influence of age on the clinical features of anti-MDA5 autoantibody-positive patients with DM remains unclear.
We retrospectively examined 40 patients with DM and anti-MDA5 autoantibodies according to age. We compared patients aged <60 and ≥60 years with respect to clinical features including laboratory test findings, high-resolution lung computed tomography data, treatment content, and complications such as infections and prognosis. We also examined clinical features between surviving and deceased patients in the older patient group.
Of 40 enrolled patients, 13 were classified as old and 27 as young. Older patients had significantly fewer clinical symptoms including arthralgia/arthritis (p < .01), skin ulceration (p = .02), and higher mortality than younger patients (p = .02) complicated with rapidly progressive ILD (RP-ILD), combination immunosuppressive therapy, and strictly controlled infections.
Clinical features and mortality of anti-MDA5 autoantibody-positive DM patients were influenced by age. Patients aged ≥60 years had a worse prognosis, and combination immunosuppressive therapy was often ineffective for RP-ILD in older patients.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Anti-MDA5 autoantibody</subject><subject>Autoantibodies - immunology</subject><subject>Dermatomyositis - drug therapy</subject><subject>Dermatomyositis - epidemiology</subject><subject>Dermatomyositis - immunology</subject><subject>Dermatomyositis - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interferon-Induced Helicase, IFIH1 - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>myositis-associated antibody</subject><subject>older people</subject><subject>rapidly progressive interstitial lung disease</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PwzAMhiMEYnz9BFCPXDqSuEmbG2h8SkNwgHPktgkEtQ0kmdD-PR3bOHKyZT-vLT2EnDI6ZbSiF6wAVQolppzycVQWtKB0hxys5nkpqdrd9iM0IYcxflAKQlVqn0yAs0KJgh-Q51nnBtdgl1mDaRFMzLzNWhN6TL5f-uiSixnG6BuHybTZt0vvGQ7J5Y_XV-K3q33rxly9zPDNHJM9i100J5t6RF5vb15m9_n86e5hdjXPG1A05ciBAZSFlKUEzktbgAEpaokVFlJQWxoKVcXQSFa3vIFxCdxWWCtQVSXhiJyv734G_7UwMenexcZ0HQ7GL6LmUApBhWJ8RMUabYKPMRirP4PrMSw1o3olU29l6pVMvZE55s42LxZ1b9q_1NbeCFyuATdYPxr79qFrdcJl54MNODQuavj_xw9eJoGw</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Yamaguchi, Koichi</creator><creator>Yamaguchi, Aya</creator><creator>Onuki, Yuji</creator><creator>Itai, Miki</creator><creator>Kashiwagi, Chiharu</creator><creator>Takehara, Kazutaka</creator><creator>Aoki, Shuhei</creator><creator>Kanaya, Azusa</creator><creator>Taguchi, Kohei</creator><creator>Umetsu, Kazue</creator><creator>Oshima, Kazuma</creator><creator>Uchida, Megumi</creator><creator>Kimura, Hayato</creator><creator>Kasahara, Morimitsu</creator><creator>Takemura, Masao</creator><creator>Hara, Kenichiro</creator><creator>Sekiguchi, Akiko</creator><creator>Motegi, Sei-ichiro</creator><creator>Muro, Yoshinao</creator><creator>Nakasatomi, Masao</creator><creator>Motohashi, Rena</creator><creator>Sakairi, Toru</creator><creator>Nakagawa, Junichi</creator><creator>Hiromura, Keiju</creator><creator>Obokata, Masaru</creator><creator>Kurabayashi, Masahiko</creator><creator>Maeno, Toshitaka</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2021</creationdate><title>Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age</title><author>Yamaguchi, Koichi ; Yamaguchi, Aya ; Onuki, Yuji ; Itai, Miki ; Kashiwagi, Chiharu ; Takehara, Kazutaka ; Aoki, Shuhei ; Kanaya, Azusa ; Taguchi, Kohei ; Umetsu, Kazue ; Oshima, Kazuma ; Uchida, Megumi ; Kimura, Hayato ; Kasahara, Morimitsu ; Takemura, Masao ; Hara, Kenichiro ; Sekiguchi, Akiko ; Motegi, Sei-ichiro ; Muro, Yoshinao ; Nakasatomi, Masao ; Motohashi, Rena ; Sakairi, Toru ; Nakagawa, Junichi ; Hiromura, Keiju ; Obokata, Masaru ; Kurabayashi, Masahiko ; Maeno, Toshitaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-a231337466763227f43e365b6a8a4650f7e03881ae61bd2c336532f8ab9398863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Anti-MDA5 autoantibody</topic><topic>Autoantibodies - immunology</topic><topic>Dermatomyositis - drug therapy</topic><topic>Dermatomyositis - epidemiology</topic><topic>Dermatomyositis - immunology</topic><topic>Dermatomyositis - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interferon-Induced Helicase, IFIH1 - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>myositis-associated antibody</topic><topic>older people</topic><topic>rapidly progressive interstitial lung disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamaguchi, Koichi</creatorcontrib><creatorcontrib>Yamaguchi, Aya</creatorcontrib><creatorcontrib>Onuki, Yuji</creatorcontrib><creatorcontrib>Itai, Miki</creatorcontrib><creatorcontrib>Kashiwagi, Chiharu</creatorcontrib><creatorcontrib>Takehara, Kazutaka</creatorcontrib><creatorcontrib>Aoki, Shuhei</creatorcontrib><creatorcontrib>Kanaya, Azusa</creatorcontrib><creatorcontrib>Taguchi, Kohei</creatorcontrib><creatorcontrib>Umetsu, Kazue</creatorcontrib><creatorcontrib>Oshima, Kazuma</creatorcontrib><creatorcontrib>Uchida, Megumi</creatorcontrib><creatorcontrib>Kimura, Hayato</creatorcontrib><creatorcontrib>Kasahara, Morimitsu</creatorcontrib><creatorcontrib>Takemura, Masao</creatorcontrib><creatorcontrib>Hara, Kenichiro</creatorcontrib><creatorcontrib>Sekiguchi, Akiko</creatorcontrib><creatorcontrib>Motegi, Sei-ichiro</creatorcontrib><creatorcontrib>Muro, Yoshinao</creatorcontrib><creatorcontrib>Nakasatomi, Masao</creatorcontrib><creatorcontrib>Motohashi, Rena</creatorcontrib><creatorcontrib>Sakairi, Toru</creatorcontrib><creatorcontrib>Nakagawa, Junichi</creatorcontrib><creatorcontrib>Hiromura, Keiju</creatorcontrib><creatorcontrib>Obokata, Masaru</creatorcontrib><creatorcontrib>Kurabayashi, Masahiko</creatorcontrib><creatorcontrib>Maeno, Toshitaka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaguchi, Koichi</au><au>Yamaguchi, Aya</au><au>Onuki, Yuji</au><au>Itai, Miki</au><au>Kashiwagi, Chiharu</au><au>Takehara, Kazutaka</au><au>Aoki, Shuhei</au><au>Kanaya, Azusa</au><au>Taguchi, Kohei</au><au>Umetsu, Kazue</au><au>Oshima, Kazuma</au><au>Uchida, Megumi</au><au>Kimura, Hayato</au><au>Kasahara, Morimitsu</au><au>Takemura, Masao</au><au>Hara, Kenichiro</au><au>Sekiguchi, Akiko</au><au>Motegi, Sei-ichiro</au><au>Muro, Yoshinao</au><au>Nakasatomi, Masao</au><au>Motohashi, Rena</au><au>Sakairi, Toru</au><au>Nakagawa, Junichi</au><au>Hiromura, Keiju</au><au>Obokata, Masaru</au><au>Kurabayashi, Masahiko</au><au>Maeno, Toshitaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2021</date><risdate>2021</risdate><volume>31</volume><issue>1</issue><spage>177</spage><epage>185</epage><pages>177-185</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-positive and age at onset ≥60 years are poor prognosis factors in polymyositis (PM) and dermatomyositis (DM) associated with interstitial lung disease (ILD) among Japanese patients. However, the influence of age on the clinical features of anti-MDA5 autoantibody-positive patients with DM remains unclear.
We retrospectively examined 40 patients with DM and anti-MDA5 autoantibodies according to age. We compared patients aged <60 and ≥60 years with respect to clinical features including laboratory test findings, high-resolution lung computed tomography data, treatment content, and complications such as infections and prognosis. We also examined clinical features between surviving and deceased patients in the older patient group.
Of 40 enrolled patients, 13 were classified as old and 27 as young. Older patients had significantly fewer clinical symptoms including arthralgia/arthritis (p < .01), skin ulceration (p = .02), and higher mortality than younger patients (p = .02) complicated with rapidly progressive ILD (RP-ILD), combination immunosuppressive therapy, and strictly controlled infections.
Clinical features and mortality of anti-MDA5 autoantibody-positive DM patients were influenced by age. Patients aged ≥60 years had a worse prognosis, and combination immunosuppressive therapy was often ineffective for RP-ILD in older patients.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>32149542</pmid><doi>10.1080/14397595.2020.1740400</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2021, Vol.31 (1), p.177-185 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_pubmed_primary_32149542 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Adult Age Factors Aged Anti-MDA5 autoantibody Autoantibodies - immunology Dermatomyositis - drug therapy Dermatomyositis - epidemiology Dermatomyositis - immunology Dermatomyositis - pathology Female Humans Immunosuppressive Agents - therapeutic use Interferon-Induced Helicase, IFIH1 - immunology Male Middle Aged Mortality myositis-associated antibody older people rapidly progressive interstitial lung disease |
| title | Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T20%3A42%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20features%20of%20dermatomyositis%20associated%20with%20anti-MDA5%20antibodies%20by%20age&rft.jtitle=Modern%20rheumatology&rft.au=Yamaguchi,%20Koichi&rft.date=2021&rft.volume=31&rft.issue=1&rft.spage=177&rft.epage=185&rft.pages=177-185&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1080/14397595.2020.1740400&rft_dat=%3Cproquest_pubme%3E2375505912%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2375505912&rft_id=info:pmid/32149542&rfr_iscdi=true |